NCT02302833 2025-07-31
Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery
M.D. Anderson Cancer Center
Phase 2 Completed
Clinical Trials
10 trialsNCT04400474 2025-06-19
CABATEN
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Completed
NCT00843037 2024-10-17
SNIPP
University Health Network, Toronto
Phase 2 Completed
NCT04860700 2024-06-12
The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma
Peking Union Medical College Hospital
Phase 2 Completed
NCT05858177 2023-05-15
MPPGL
Peking Union Medical College Hospital
Phase 2 Completed
NCT01371201 2022-08-04
FIRSTMAPPP
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Completed
NCT01967576 2021-01-06
Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01635907 2020-04-14
Dovitinib in Neuroendocrine Tumors
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT01560260 2018-09-21
Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT01413503 2018-09-18
A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors
University of California, San Francisco
Phase 2 Completed